Good Distribution Practices

Silverdale Healthcare Ltd complies with the principles and guidelines on GDP of Medicinal Products for Human Use as set out under

  • Human medicines Regulations 2012 (SI 2012/1916)
  • Falsified Medicines Directive 2011/62/EU
  • Medicines for Human Use (Marketing Authorisations etc) Regulations 1994 (SI 1994/3144)
  • Guidelines on GDP of medicinal products for human use (94/C63/03)
  • Council Directive 92/25/EC on the wholesale distribution of medicinal products for human use
  • Rules and Guidance for the Pharmaceuticals Distributors 2017 (The Green Guide)
  • Relevant sections of Directive 2001/83/EC as amended

It is critical to patient safety that Silverdale Healthcare Ltd and all parties within our international supply-chain maintain the quality and authenticity of the products supplied. In order to monitor and uphold safety; the highest standards are implement through strict audited policies on:

  • Personnel and Training
  • Documentation, Procedures & Records
  • Premises and Equipment
  • Deliveries and Returns of Products
  • Emergency Plan, Recalls and Anti-Counterfeit Measures
  • Inspections and Self-Inspections
  • Provision of information to EC authorities

Our most recent audit by the Medicines and Healthcare Products Regulatory Agency (MHRA) was in December 2016 and Silverdale Healthcare was credited for its high standards, policies and procedures and authorised under the terms of our Licences.

click here  for further information on our Quality Systems or to request a copy of our Wholesale Dealers Authorisation.